亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

医学 前列腺癌 临床终点 内科学 醋酸阿比特龙酯 安慰剂 多西紫杉醇 恩扎鲁胺 肿瘤科 雄激素剥夺疗法 强的松 泌尿科 癌症 随机对照试验 病理 雄激素受体 替代医学
作者
Fred Saad,Antoine Thiery-Vuillemin,Paweł Wiechno,B. Yа. Alekseev,Núria Sala,Robert H. Jones,Ivo Kocák,Vincenzo Emanuele Chiurì,Jacek Jassem,Aude Fléchon,Charles H. Redfern,Jinyu Kang,Joseph E. Burgents,Christopher Gresty,Arnold Degboe,Noel W. Clarke
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (10): 1297-1307 被引量:24
标识
DOI:10.1016/s1470-2045(22)00498-3
摘要

Results of this double-blind, phase 2 trial showed patients with metastatic castration-resistant prostate cancer given olaparib plus abiraterone versus placebo plus abiraterone had significantly improved progression-free survival. Here, we present an exploratory analysis of pain and health-related quality of life (HRQOL).This double-blind, randomised, placebo-controlled, phase 2 trial was conducted across 41 urological oncology sites in 11 countries in Europe and North America. Eligible patients were aged 18 years or older, had metastatic castration-resistant prostate cancer, and had previously received docetaxel and up to one additional line of previous chemotherapy. Metastatic castration-resistant prostate cancer was defined as increasing prostate-specific antigen (PSA) concentration or other signs of disease progression despite androgen-deprivation therapy and serum testosterone concentrations at castrate levels (≤50 ng/dL), and with at least one metastatic lesion on bone scan, CT, or MRI. Eligible patients were randomly assigned (1:1) to receive oral olaparib (300 mg twice per day) plus oral abiraterone (1000 mg once a day) and oral prednisone or prednisolone (5 mg twice a day) or placebo plus abiraterone (1000 mg once a day) and prednisone or prednisolone (5 mg twice a day). Randomisation was done without stratification and by use of an interactive voice or web response system. A randomised treatment kit ID number was assigned sequentially to each patient as they became eligible. The primary endpoint (radiographic progression-free survival) has previously been reported. HRQOL was a prespecified exploratory patient-reported outcome. Patients were asked to complete the Brief Pain Inventory-Short Form (BPI-SF), single-item worst bone pain, Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, and EuroQol-5 five-dimension five level (EQ-5D-5L) assessment at baseline, at weeks 4, 8, and 12, then every 12 weeks until treatment discontinuation. Prespecified outcomes were change from baseline in BPI-SF worst pain, single-item worst bone pain and FACT-P Total Outcome Index (TOI) scale scores, time to deterioration in BPI-SF worst pain and worst bone pain, and assessment of the EQ-5D-5L pain and discomfort domain. All analyses were exploratory and done in the full analysis set (all randomly assigned patients, including patients who were randomly assigned but did not subsequently go on to receive study treatment), with the exception of mean baseline and total change from baseline analyses, for which we used the population who had a valid baseline and at least one post-baseline assessment. This trial is registered with Clinicaltrials.gov, NCT01972217, and is no longer recruiting patients.Between Nov 25, 2014, and July 14, 2015, 171 patients were assessed for eligibility. 29 patients were excluded, and 142 were enrolled and randomly assigned to receive olaparib and abiraterone (n=71) or placebo and abiraterone (n=71). Data cutoff was Sept 22, 2017. Median follow-up was 15·9 months (IQR 8·1-25·5) in the olaparib plus abiraterone group and 24·5 months (8·1-27·6) in the placebo plus abiraterone group. Questionnaire compliance was generally high (43-100%). Least-squares mean changes from baseline in BPI-SF worst pain, single-item worst bone pain, and FACT-P TOI remained stable across all visits for patients in both treatment groups. Adjusted mean change in FACT-P TOI from baseline across all visits was -0·10 (95% CI -2·50 to 2·71) in the olaparib plus abiraterone group and -1·20 (-4·15 to 1·74) in the placebo plus abiraterone group (difference 1·30, 95% CI -2·70 to 5·30; p=0·52). Time to deterioration in pain was similar in both groups (BPI-SF worst pain HR 0·90 [95% CI 0·62-1·32], p=0·30; worst bone pain HR 0·85 [0·59-1·22], p=0·18). Improvement rates in the pain and discomfort domain of the EQ-5D-5L were similar in both groups from baseline to week 48, beyond which a higher proportion of patients in the olaparib plus abiraterone arm reported an improvement compared to the placebo plus abiraterone group.In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone. In this phase 2 trial, a statistically significant radiographic progression-free survival benefit was observed with the olaparib plus abiraterone combination. These results suggest that the improved survival benefits observed when combining olaparib with abiraterone does not result in different HRQOL compared with placebo plus abiraterone. Phase 3 studies are required to validate these results.AstraZeneca and Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
5秒前
369ninja发布了新的文献求助10
10秒前
可靠往事完成签到,获得积分10
12秒前
自由的梦山完成签到,获得积分10
22秒前
喜悦如萱完成签到,获得积分10
28秒前
30秒前
35秒前
369ninja发布了新的文献求助10
41秒前
54秒前
学霸业的应助被369ninja采纳,获得10
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
43tg完成签到,获得积分10
1分钟前
qfhbg完成签到,获得积分10
1分钟前
落后哈密瓜完成签到,获得积分10
1分钟前
wetg完成签到,获得积分10
1分钟前
学霸业的应助被369ninja采纳,获得10
1分钟前
portik完成签到,获得积分10
1分钟前
要减肥的菀完成签到,获得积分10
1分钟前
hgjk完成签到,获得积分10
1分钟前
1分钟前
sdf完成签到,获得积分10
1分钟前
VDC的应助被369ninja采纳,获得30
1分钟前
amz完成签到,获得积分10
1分钟前
adefgv完成签到,获得积分10
1分钟前
科目三的应助被科研通管家采纳,获得10
1分钟前
fhjg完成签到,获得积分10
1分钟前
Nole的应助被369ninja采纳,获得10
2分钟前
jtk完成签到,获得积分10
2分钟前
pwn完成签到,获得积分10
2分钟前
2分钟前
虚心的手套完成签到,获得积分10
2分钟前
wh完成签到,获得积分10
2分钟前
369ninja发布了新的文献求助10
2分钟前
2分钟前
我是笨蛋完成签到 ,获得积分10
2分钟前
CodeCraft的应助被369ninja采纳,获得10
2分钟前
fsw完成签到,获得积分10
2分钟前
sd完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808464
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557361
邀请新用户注册赠送积分活动 2478958